注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
I-Mab是一家总部位于中国的公司,主要从事创新全球生物技术的开发。该公司的主要业务包括从事创新记录、开发创新候选药物以及进行资产和商业化的临床验证。该公司在研产品由十项临床阶段资产和十项临床前资产组成,其中七项资产已进入二期或三期临床试验阶段。其管道预计将产生三个近期NDA申请和/或产品发布,包括用于多发性骨髓瘤(MM)的felzartamab、用于儿科生长激素缺乏症(PGHD)的eftansomatropin alfa,以及潜在的用于骨髓增生异常综合征(MDS)的lemzoparlimab,以及后来用于急性髓性白血病(AML)和非霍奇金淋巴瘤(NHL)的药物。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Xi Liu | - | 2021 | Independent Director |
Patricia LoRusso | - | 2019 | Member of Scientific Advisory Board |
Pamela M. Klein | 63 | 2020 | Interim Chairperson |
Howard L. Weiner | 77 | 2019 | Member of Scientific Advisory Board |
Timothy A. Yap | 49 | 2019 | Member of Scientific Advisory Board |
Roy Steven Herbst | 61 | 2019 | Member of Scientific Advisory Board |
Chia-Hung Yang | 61 | 2020 | Independent Director |
Jun Ma | - | 2020 | Member of Scientific Advisory Board |
Wei Fu | 42 | 2018 | Director |
Chun Kwok Au | 51 | 2020 | Independent Director |
Rong Shao | 62 | 2021 | Independent Director |
Yi-Long Wu | - | 2019 | Member of Scientific Advisory Board |
Chen Dong | - | 2020 | Member of Scientific Advisory Board |
Eric K. Rowinsky | 67 | 2019 | Member of Scientific Advisory Board |
Ruyi He | 62 | 2021 | Independent Director |
Raj Kannan | 60 | 2023 | CEO & Director |
Shuai Chen | 50 | 2023 | Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核